Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + docetaxel + sintilimab
- Development stage
- Unknown
- Lead developer
- Suzhou Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy regimen consisting of cisplatin (a platinum-based chemotherapy agent), docetaxel (a taxane chemotherapy agent), and sintilimab (an immune checkpoint inhibitor). The combination is being studied for the treatment of advanced cancers, including gastric cancer and non-small cell lung cancer (NSCLC). Sintilimab is a recombinant fully human immunoglobulin G4 monoclonal antibody that blocks the interaction between PD-1 and PD-L1, while cisplatin and docetaxel are cytotoxic chemotherapy agents.
- Brand names
- Tyvyt
- Other names
- cisplatin + tocetaxel + sintilimabsintilimab + cisplatin + docetaxelsintilimab + TP chemotherapyTP regimen combined with PD-1 inhibitors
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNAMicrotubule
Beyond the preview
Go deeper on cisplatin + docetaxel + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + docetaxel + sintilimab.